Identifying high‐risk multiple myeloma patients: A novel approach using a clonal gene signature
International Journal of Cancer · 2024
DOI: 10.1002/ijc.35057 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Jian-Rong Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Gene Expression Profiling. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
Multiple myeloma (MM) is a heterogeneous disease with a small subset of high‐risk patients having poor prognoses. Identifying these patients is crucial for treatment management and strategic decisions. In this study, we developed a novel computational framework to define prognostic gene signatures by selecting genes with expression driven by clonal copy number alterations. We applied this framework to MM and developed a clonal gene signature (CGS) consisting of 22 genes and evaluated in five independent datasets. The CGS provided significant prognostic values after adjusting for well‐established factors including cytogenetic abnormalities, International Staging System (ISS), and Revised ISS (R‐ISS). Importantly, CGS demonstrated higher performance in identifying high‐risk patients compared to the GEP70 and SKY92 signatures recommended for prognostic stratification of MM. CGS can further stratify patients into subgroups with significantly differential prognoses when applied to the high‐ and low‐risk groups identified by GEP70 and SKY92. Additionally, CGS scores are significantly associated with patient response to dexamethasone, a commonly used treatment for MM. In summary, we proposed a computational framework that requires only gene expression data to identify CGSs for prognosis prediction. CGS provides a useful biomarker for improving prognostic stratification in MM, especially for identifying the highest‐risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.
- Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
- Genetics and Genomics Graduate Program, Baylor College of Medicine, Houston, Texas, USA.
- Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
ORCID-Profile: Chao Cheng
Förderung
- NCI NIH HHS
- NIH HHS
- Cancer Prevention and Research Institute of Texas
- National Cancer Institute
Zitieren
APA
Li, J. R., Wang, C., & Cheng, C. (2024). Identifying high‐risk multiple myeloma patients: A novel approach using a clonal gene signature. International Journal of Cancer. https://doi.org/10.1002/ijc.35057
Vancouver
Li JR, Wang C, Cheng C. Identifying high‐risk multiple myeloma patients: A novel approach using a clonal gene signature. International Journal of Cancer. 2024. doi:10.1002/ijc.35057
BibTeX
@article{Li2024,
author = {Li, Jian-Rong and Wang, Christiana and Cheng, Chao},
title = {Identifying high‐risk multiple myeloma patients: A novel approach using a clonal gene signature},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.35057}
}
EUVIMED